
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

3 National Institute for Health and Care Excellence. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. London: National Institute for Health and Care Excellence (UK), 2020.
4 Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). *Eur Heart J* 2020; **41:** 543–603.
5 Roncon L, Zuin M, Zonzin P. Age-adjusted D-dimer cut-off levels to rule out venous thromboembolism in COVID-19 patients. *Thromb Res* 2020; **190:** 102.

## Authors' reply

We appreciate the issues related to normal age-related D-dimer concentrations raised by Marco Zuin and colleagues. The ACTION study[1] is a randomised trial designed pragmatically to answer the question of whether patients hospitalised with COVID-19 and elevated D-dimer concentration, without another indication for anticoagulation, should routinely receive therapeutic anticoagulation with the factor Xa inhibitor, rivaroxaban. We found that rivaroxaban 20 mg once daily for 30 days had no benefit and significantly increased bleeding compared with in-hospital prophylactic heparin.

Early in the COVID-19 pandemic, observational data suggested that thrombotic events were high in patients with COVID-19 and even higher among patients with an elevated D-dimer concentration.[2] In light of the available information at the time, coupled with the fact that the D-dimer concentration of many patients with COVID-19 was measured when they were hospitalised, we included an elevated D-dimer concentration, defined as above the assay (not age-adjusted) upper limit of normal in each site, as an inclusion criterion for the ACTION trial. D-dimer concentrations are not routinely measured to guide therapeutic anticoagulation decision making in patients without COVID-19,[3] and the purpose of enrolling patients with an elevated D-dimer concentration in ACTION was to increase the trial population's risk of thrombotic events and not to establish D-dimer concentrations as a diagnostic tool to guide therapeutic anticoagulation in patients hospitalised with COVID-19.

A prespecified subgroup analysis of ACTION showed that the main results were consistent, irrespective of D-dimer concentrations.[1] Similar results have been shown in other randomised trials investigating anticoagulation in patients with COVID-19, in which D-dimer concentrations at presentation (elevated *vs* normal *vs* not collected) did not influence the main results.[4,5] Furthermore, when we used age-adjusted D-dimer upper limits of normal, as proposed by Zuin and colleagues, we found that most (>90%) patients over the age of 50 years still had an elevated age-adjusted D-dimer concentration at study entry. Not surprisingly, when we excluded the fewer than 10% of patients who did not have an elevated age-adjusted D-dimer concentration, our main results remained consistent with those in the overall population (win ratio 0·87 [95% CI 0·59–1·26]). Therefore, the results from the ACTION trial are relevant, robust, and provide high-quality evidence to avoid the routine use of therapeutic rivaroxaban—in the absence of another evidence-based indication for oral anticoagulation—in patients hospitalised with COVID-19, irrespective of D-dimer concentration.

RDL reports institutional research grants from Bristol Myers Squibb, GlaxoSmithKline, Medtronic, Pfizer, and Sanofi; consulting fees from Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Medtronic, Merck, Pfizer, Portola, Sanofi, and Eidos; honoraria from Bristol Myers Squibb and Pfizer; support for attending meetings, travel, or both, from Bristol Myers Squibb and Pfizer; and data safety monitoring board or advisory board participation for IQVIA. PGMdBeS reports institutional research grants from Bayer, Pfizer, and Roche Diagnostics; and honoraria from Roche Diagnostics. RHMF reports institutional research grants from Bayer, Aché, Health Canada, CytoDin, EMS, Pfizer, AstraZeneca, and the Brazilian Ministry of Health; consulting fees from Servier; honoraria from AstraZeneca, Bayer, and Servier; support for attending meetings, travel, or both, from AstraZeneca and Bayer; and advisory board participation for Biomm. JHA reports institutional research grants from Bayer, Bristol Myers Squibb, Cryolife, CSL Behring, Ferring, Humacyte, GlaxoSmithKline, and XaTek; consulting fees from Akros, AtriCure, Bristol Myers Squibb, Cryolife, Ferring, GlaxoSmithKline, Janssen, Pfizer, and Portola; honoraria from Akros, AtriCure, Bristol Myers Squibb, Ferring, GlaxoSmithKline, Janssen, Pfizer, and Portola; support for attending meetings, travel, or both, from Bristol Myers Squibb and CryoLife; and data safety monitoring board or advisory board participation for AbbVie. OB reports institutional research grants from AstraZeneca, Pfizer, Bayer, Boehringer Ingelheim, Amgen, Novartis, and Servier.

**Renato D Lopes, Pedro Gabriel Melo de Barros e Silva, Remo H M Furtado, John H Alexander, Otavio Berwanger*
**renato.lopes@duke.edu**

Duke University Medical Center and Duke Clinical Research Institute, Durham, NC 27701, USA (RDL, JHA); Brazilian Clinical Research Institute, Sao Paulo, Brazil (PGMdBeS); Academic Research Organization, Hospital Israelita Albert Einstein, Sao Paulo, Brazil (RHMF, OB)

1 Lopes RD, de Barros e Silva PGM, Furtado RHM, et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. *Lancet* 2021; **397:** 2253–63.
2 Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost* 2020; **18:** 844–47.
3 Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. *Blood Adv* 2020; **4:** 4693–738.
4 The REMAP-CAP, ACTIV-4a, and ATTACC Investigators. Therapeutic anticoagulation with heparin in critically ill patients with COVID-19. *N Engl J Med* 2021; published online Aug 4. https://doi.org/10.1056/NEJMoa2103417.
5 The ATTACC, ACTIV-4a, and REMAP-CAP Investigators. Therapeutic anticoagulation with heparin in noncritically ill patients with COVID-19. *N Engl J Med* 2021; published online Aug 4. https://doi.org/10.1056/NEJMoa2105911.

## Department of Error

*Shikino K, Sato R, Hanazawa N, Ikusaka M. Chronic clicking tinnitus due to palatal tremor: essential or secondary?* Lancet *2021;* **397:** *e16*—In this Clinical Picture, Manato Yasuda has been added as an author. In the second sentence of the fifth paragraph, treatment dose has been corrected to 3 mg clonazepam orally per day. These corrections have been made to the online version as of Oct 7, 2021.